title: Omalizumab for patients with severe and therapy-refractory atopic eczema?
authors.affiliation: Department of Dermatology and Allergy, Technical University Munich, Munich, Germany. christian.andres@lrz.tu-muenchen.de
authors.forename: Christian
authors.initials: C
authors.lastname: Andres
authors.forename: Benedetta
authors.initials: B
authors.lastname: Belloni
authors.forename: Martin
authors.initials: M
authors.lastname: Mempel
authors.forename: Johannes
authors.initials: J
authors.lastname: Ring
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000235:genetics; D000069444:Omalizumab; D012333:RNA, Messenger / Q000032:analysis
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D012333:RNA, Messenger; D000069444:Omalizumab; D007073:Immunoglobulin E